Therapy News and Research

RSS

$Denosumab reduces fracture risk in men receiving androgen-deprivation therapy for prostate cancer$

Denosumab reduces fracture risk in men receiving androgen-deprivation therapy for prostate cancer

Twice-yearly treatment with denosumab, a new targeted therapy to stop bone loss, increased bone density and prevented spinal fractures in men receiving androgen-deprivation therapy for prostate cancer.

11 Aug 2009

AIDS Research Center earns $7.5 million grant renewal

The University of Alabama at Birmingham (UAB) Center for AIDS Research (CFAR) has won a $7.5 million grant to continue its work in the research, prevention and treatment of human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS).

11 Aug 2009

Integrated Medical Systems receives U.S. Army order for "suitcase" intensive care unit

Integrated Medical Systems, Inc., a medical technology systems integrator transforming critical care, announced that it has received a commitment for approximately $3.25 million in funding from the U.S. Army's Medical Research Material Command for acquisition and ongoing development of the company's MedEx 1000(TM) "suitcase" intensive care unit (ICU).

11 Aug 2009

New approach to remove toxic agent that causes myotonic dystrophy

Cell biologists from the Radboud University Nijmegen Medical Centre (Nijmegen, the Netherlands) describe a new approach to remove the toxic agent that causes the neuromuscular disease myotonic dystrophy. Their findings are published in the scientific journal The Proceedings of the National Academy of Sciences.

11 Aug 2009

Oxygen nanosensor could improve tumor imaging

A new material developed at the University of Virginia - an oxygen nanosensor that couples a light-emitting dye with a biopolymer - simplifies the imaging of oxygen-deficient regions of tumors. Such tumors are associated with increased cancer aggressiveness and are particularly difficult to treat.

11 Aug 2009

Gene Signal publishes phase I data on GS-101 for diseases of the eye

Gene Signal, a company focused on developing innovative drugs to manage angiogenesis based conditions, has announced publication of data from a phase I study demonstrating that the antisense oligonucleotide GS-101 (eye drops) is safe, with no signs of intolerability following administration to healthy volunteers.

11 Aug 2009

Genzyme updates on Cerezyme supply plus 2009 financials

Genzyme Corporation (NASDAQ: GENZ) today provided an update on the impact of Cerezyme® (imiglucerase for injection) supply constraints on patient treatment regimens and on the company’s 2009 financial results. The company’s Fabrazyme® (agalsidase beta) supply constraint period, Fabrazyme dose conservation guidelines for patients, and Fabrazyme financial guidance are unchanged.

11 Aug 2009

Predictors of disease behavior change in patients with Crohn's disease

Using the Vienna classification system, it has been shown in clinic-based cohorts that there can be a significant change in disease behavior over time, whereas disease location remains relatively stable. Clinical and environmental factors as well as medical therapy might be relevant in predicting disease behavior change in patients with CD.

11 Aug 2009

Depomed reports promising results in phase I trial for DM-1992 in Parkinson’s

Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson’s patients, DM-1992, Depomed’s investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa’s efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.

11 Aug 2009

STAT3 is required for proliferation and maintenance of multipotency in glioblastoma stem cells

In a study published online in advance of print in Stem Cells, Tufts researchers report that the STAT3 gene regulates cancer stem cells in brain cancer. Cancer stem cells have many characteristics of stem cells and are thought to be the cells that drive tumor formation. The researchers report that STAT3 could become a target for cancer therapy, specifically in Glioblastoma multiforme (GBM), a type of malignant and aggressive brain tumor.

11 Aug 2009

Discovery of a potential target for metastatic cancer

The deadliest part of the cancer process, metastasis, appears to rely on help from macrophages, potent immune system cells that usually defend vigorously against disease, researchers at Albert Einstein College of Medicine of Yeshiva University report.

11 Aug 2009

Childhood cancer survivors treated with radiation may have an increased risk of diabetes

Childhood cancer survivors treated with total body or abdominal radiation may have an increased risk of diabetes, according to a report in the August 10/24 issue of Archives of Internal Medicine, one of the JAMA/Archives journals. This correlation does not appear to be related to patients’ body mass index or physical inactivity.

11 Aug 2009

Insulin and type 2 diabetes - fears are largely unfounded

People diagnosed with type 2 diabetes often resist taking insulin because they fear gaining weight, developing low blood sugar and seeing their quality of life decline.

11 Aug 2009

Eiger Biopharmaceuticals starts CLEAN-1 HCV phase 1B trial

Eiger BioPharmaceuticals, Inc., a biotechnology company developing antiviral therapies, announced today that the first patients have been dosed in an innovative clinical trial in patients chronically infected with the hepatitis C virus (HCV). The trial, run in centers in Australia and New Zealand, will investigate the antiviral effect of clemizole monotherapy in the absence of interferon.

10 Aug 2009

New hope for sufferers of alpha-1 antitrypsin deficiency

Researchers at the University of Massachusetts Medical School and the University of Florida in Gainesville have safely given new, functional genes to patients with a hereditary defect that can lead to fatal lung and liver diseases, according to clinical trial findings slated to appear this week in the online early edition of the Proceedings of the National Academy of Science.

10 Aug 2009

Hythiam, Inc. announces Q2 financials

Hythiam, Inc. (NASDAQ:HYTM) today announced financial results for the second quarter ended June 30, 2009, which include the consolidated results from Comprehensive Care Corporation (CompCare) through January 20, 2009, the disposition date. As a result of the January 20, 2009 sale, the Company’s results treat CompCare as a Discontinued Operation.

10 Aug 2009

Vulvodynia, the most frequent cause of painful sex

PAINFUL SEX. It's a secret that millions of women live with in embarrassment and isolation. Until now. . .

10 Aug 2009

Association of Specialty Professors announces the 2009 T. Franklin Williams scholars

The Association of Specialty Professors (ASP) is pleased to announce the eighth class of T. Franklin Williams Scholars. These scholars are recipients of two- to four-year career development awards funded by a generous grant from the Atlantic Philanthropies (USA) Inc. and the John A. Hartford Foundation, and co-sponsored by 12 internal medicine specialty societies.

10 Aug 2009

Array Biopharma reports Q4 and full year 2009 financials

Array reported revenue of $5.5 million for the fourth quarter of fiscal 2009, compared to revenue of $6.1 million for the same period in fiscal 2008. Array invested $21.3 million in proprietary research and development for the quarter to advance its seven wholly-owned drugs in clinical development and select discovery programs.

10 Aug 2009